Table 3.
S. No. | Nanoplatforms (NF) | Target Ligand | Therapeutic Features | Ref. |
---|---|---|---|---|
1 | Fe3O4 NPs | Lactoferrin | Imaging | [51] |
2 | Polymersome | G23 peptide | Drug Carrier | [52] |
3 | RGD-QDs | RGD peptide | NI Imaging | [79] |
4 | EGFpep-Au NPs | EGF peptide | PDT | [80] |
5 | G4-DOX-PEG-Tf-TAM | Transferrin (Tf) | Drug delivery | [81] |
6 | ANG-PEG-NP | Angiopep-2 | Drug delivery | [46] |
7 | PBCA NPs | Polysorbate 80 | Delivery | [82] |
8 | DTX-ANG20/TAT10-Ms | Angiopep-2 | Imaging, drug delivery | [83] |
9 | ANG-IMNPs | angiopep-2 | PTT/PDT | [84] |
10 | Tw-Mtx-Tf-NP | Transferrin | Drug delivery | [67] |
11 | AP-PLGA-NPs | Polysorbate | Drug delivery | [85] |
12 | TAT-Au NP | TAT peptide | Drug delivery, MR imaging | [54] |
13 | DOX-EDT-IONPs | Passive | Chemotherapy | [86] |
14 | (ICG)-loaded polymeric NPs | Passive | Imaging, PTT | [74] |
15 | 131I-Au PENPs-CTX | Chlorotoxin | Imaging, Radio therapy | [87] |
16 | MoS2–ICG NSs | Passive | PA Imaging | [88] |
17 | mPEG-PLGA NPs | Passive | Dual drug delivery | [89] |
18 | LP-iDOPE | Passive | NIR imaging, Photo-immune therapy | [90] |
19 | Fe3O4 NPs | G23 peptide, passive | MR Imaging, drug delivery | [91,92] |
20 | B16-PCL-ICG NPs | Cell membrane | Fluorescence imaging, PTT | [74] |
21 | BLIPO-ICG NPs | Cell membrane | Fluorescence imaging, PTT | [93] |
Abbreviations: arginine-glycine-aspartate (RGD), Quantum dots (QDs), epidermal growth factor peptide (EGFpep), Doxorubicin (DOX), Polyethylene glycol (PEG), Tamoxifen (TAM), Angiopep (ANG), poly(n-butylcyanoacrylate) NPs (PBCA NPs), docetaxel (DTX), transactivator of transcription (TAT), methotrexate (MTX), Acetylpuerarin (AP), poly(lactic-co-glycolic acid) (PLGA), trimethoxysilylpropyl-ethylenediamine triacetic acid (EDT), iron oxide nanoparticles (IONPs), Indocyanine green (ICG), chlorotoxin (CTX), polyethylenimine NPs (PENPs), Molybdenum sulfide (MOS2), liposomally formulated phospholipid-conjugated indocyanine green (LP-iDOPE), poly(ε-caprolactone)(PCL), liposome (BLIPO).